Scarica l'app Stockscreener
3.98
0.75%
-0.03
Dopo l'orario di chiusura:
3.98
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché BLRX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$4.01
Aprire:
$4.02
Volume 24 ore:
21,349
Relative Volume:
0.03
Capitalizzazione di mercato:
$16.97M
Reddito:
-
Utile/perdita netta:
$-60.61M
Rapporto P/E:
-4.4222
EPS:
-0.9
Flusso di cassa netto:
$-22.91M
1 W Prestazione:
-11.75%
1M Prestazione:
-12.91%
6M Prestazione:
+11.80%
1 anno Prestazione:
+406.75%
Intervallo 1D:
$3.80
$4.08
Intervallo di 1 settimana:
$3.80
$4.69
Portata 52W:
$0.0815
$7.7699
Bioline Rx Ltd Adr Stock (BLRX) Company Profile
Nome
Bioline Rx Ltd Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta BLRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BLRX
Bioline Rx Ltd Adr
|
3.98 | 14.92M | 0 | -60.61M | -22.91M | -0.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Bioline Rx Ltd Adr Stock (BLRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2017-05-18 | Aggiornamento | Maxim Group | Hold → Buy |
| 2017-02-13 | Iniziato | Rodman & Renshaw | Buy |
| 2016-08-12 | Downgrade | Maxim Group | Buy → Hold |
| 2015-08-17 | Reiterato | Maxim Group | Buy |
| 2015-07-27 | Reiterato | ROTH Capital | Buy |
| 2015-06-22 | Iniziato | JMP Securities | Mkt Outperform |
Mostra tutto
Bioline Rx Ltd Adr Borsa (BLRX) Ultime notizie
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX) and Gilead Sciences (GILD) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Esperion (ESPR) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: NextCure (NXTC), Lexaria Bioscience (LEXX) and Travere Therapeutics (TVTX) - The Globe and Mail
BioLineRx Ltd. Approves Key Proposals at Annual Meeting - TipRanks
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Capricor Therapeutics (CAPR) and Abbott Laboratories (ABT) - The Globe and Mail
Promising Phase 2 Trial Results Drive Buy Rating for BioLine RX in mPDAC Treatment - TipRanks
BioLineRx ADR: Positive Earnings Call Highlights and Challenges - MSN
Analysts Offer Insights on NA Companies: Tempus AI, Inc. Class A (TEM) and Rapport Therapeutics, Inc. (RAPP) - The Globe and Mail
BioLineRx upgraded to Buy from Hold at JonesResearch - Yahoo Finance
BioLineRx reports promising pancreatic cancer trial data By Investing.com - Investing.com South Africa
BioLineRx Stock Jumps On Positive Data from Pilot Phase Of Pancreatic Cancer Drug Trial: Retail Cheers The ‘Buy’ Rating By Stocktwits - Investing.com India
BioLineRx announces new data from Phase 2 combination trial of motixafortide - TipRanks
Jones Trading raises BioLineRx stock rating, targets $12 By Investing.com - Investing.com South Africa
Jones Trading raises BioLineRx stock rating, targets $12 - Investing.com India
BioLineRx Presents Promising Phase 2 Data at ASCO 2025 for Pancreatic Cancer Trial - TipRanks
BioLineRx reports promising pancreatic cancer trial data - Investing.com
JonesTrading Reaffirms Their Hold Rating on Bioline RX Ltd Sponsored ADR (BLRX) - The Globe and Mail
Jones Trading maintains Hold on BioLineRx stock amid royalty prospects - Investing.com India
Jones Trading maintains Hold on BioLineRx stock amid royalty prospects By Investing.com - Investing.com South Africa
H.C. Wainwright Maintains Buy Rating, $26 Target on BioLineRx Stock - Investing.com
H.C. Wainwright Maintains Buy Rating, $26 Target on BioLineRx Stock By Investing.com - Investing.com South Africa
BioLineRx: Strong Financials and Promising Clinical Developments Drive Buy Rating - TipRanks
BioLineRx Ltd. Reports Q1 2025 Financial Results - TipRanks
BioLineRx Q1 Earnings Rise Despite Fall In Revenue: Retail Stays Super Confident By Stocktwits - Investing.com India
BioLineRx Reports Q1 2025 Financial Results and Strategic Updates - TipRanks
Options Volatility and Implied Earnings Moves Today, May 27, 2025 - TipRanks
BioLineRx Ltd. Schedules Annual Shareholder Meeting for June 2025 - TipRanks
Analysts Offer Insights on Healthcare Companies: VYNE Therapeutics (VYNE) and CVRx (CVRX) - The Globe and Mail
BioLineRx stock rating cut to Hold at Jones Trading - Investing.com
BLRX stock touches 52-week low at $2.85 amid sharp annual decline - Investing.com
H.C. Wainwright raises BioLineRx stock target to $26 - Investing.com India
BioLineRx Ltd. Reports 2024 Financial Results and Strategic Progress - TipRanks
BioLineRx Earnings Call: Strategic Shifts and Growth - TipRanks
BioLineRx price target adjusted to $26 at H.C. Wainwright after reverse split - TipRanks
Options Volatility and Implied Earnings Moves This Week, March 31 – April 03, 2025 - The Globe and Mail
BioLineRx Reports Strong 2024 Financial Results and Strategic Advancements - TipRanks
Bioline RX Ltd Sponsored ADR to Host Earnings Call - ACCESS Newswire
Investor Network: Bioline RX Ltd Sponsored ADR to Host Earnings Call - ACCESS Newswire
BLRX: Aphexda Transition Progressing - Research Tree
BioLineRx stock hits 52-week low at $3.24 amid sharp decline - Investing.com India
BioLineRx Outlines Strategic Vision and Financial Outlook After Key Licensing Deals - TipRanks
BioLineRx announces strategic shift with licensing deals - Investing.com
BioLineRx Announces 1:40 ADS Ratio Change, Confirms $29.5M Cash Runway Through 2026 - Stock Titan
BioLineRx stock touches 52-week low at $0.14 amid downturn - Investing.com
BiolineRx Announces Major Direct Offering to Bolster Operations - TipRanks
BioLineRx Announces $10 Million Direct Offering to Fuel Growth - TipRanks
BioLineRx Raises $10M in Direct Offering at $0.20 Per ADS with Matching Warrants - Stock Titan
BioLineRx stock hits 52-week low at $0.21 amid market challenges - Investing.com
BioLineRx Secures Key Deals to Boost Shareholder Value - TipRanks
Earnings call: BioLineRx announces Q3 results and strategic shifts - Investing.com
BioLineRx, Ayrmid enter license agreement for motixafortide through Gamida Cell - Yahoo Finance
Bioline Rx Ltd Adr Azioni (BLRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.43%
2.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):